<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-id journal-id-type="hwp">ofids</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5781392</article-id><article-id pub-id-type="doi">10.1093/ofid/ofu051.99</article-id><article-id pub-id-type="publisher-id">ofu051</article-id><article-categories><subj-group subj-group-type="heading"><subject>IDWeek 2014 Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Oral Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>1211<break/>A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kontoyiannis</surname><given-names>Dimitrios</given-names></name><xref ref-type="aff" rid="sa99-af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giladi</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="sa99-af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Misun</given-names></name><xref ref-type="aff" rid="sa99-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nucci</surname><given-names>Marcio</given-names></name><xref ref-type="aff" rid="sa99-af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Raad</surname><given-names>Issam</given-names></name><xref ref-type="aff" rid="sa99-af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bow</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="sa99-af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Morrison</surname><given-names>Vicki a.</given-names></name><xref ref-type="aff" rid="sa99-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Baddley</surname><given-names>John</given-names></name><xref ref-type="aff" rid="sa99-af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Zeiher</surname><given-names>Bernhardt</given-names></name><xref ref-type="aff" rid="sa99-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Maher</surname><given-names>Rochelle</given-names></name><xref ref-type="aff" rid="sa99-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wenmei</given-names></name><xref ref-type="aff" rid="sa99-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Marr</surname><given-names>Kieren a.</given-names></name><xref ref-type="aff" rid="sa99-af9">9</xref></contrib></contrib-group><aff id="sa99-af1"><label>1</label>Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX</aff><aff id="sa99-af2"><label>2</label>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel</aff><aff id="sa99-af3"><label>3</label>Astellas Pharma Global Development, Northbrook, IL</aff><aff id="sa99-af4"><label>4</label>Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro - RJ, Brazil</aff><aff id="sa99-af5"><label>5</label>Infectious Diseases, Infection Control &#x00026; Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX</aff><aff id="sa99-af6"><label>6</label>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada</aff><aff id="sa99-af7"><label>7</label>University of Minnesota, VAMC, Minneapolis, MN</aff><aff id="sa99-af8"><label>8</label>Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL</aff><aff id="sa99-af9"><label>9</label>Departments of Medicine and Oncology, Johns Hopkins University, Baltimore, MD</aff><author-notes><fn id="TN206" fn-type="con"><p><bold>Session:</bold> 148. Fungal Infections</p></fn><fn id="TN207" fn-type="con"><p>Friday, October 10, 2014: 2:00 PM</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub" iso-8601-date="2014-12-01"><month>12</month><year>2014</year></pub-date><volume>1</volume><issue>Suppl 1</issue><issue-title>IDWeek 2014 Abstracts</issue-title><fpage seq="c">S37</fpage><lpage>S37</lpage><permissions><copyright-statement>&#x000a9; The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xlink:href="ofu051.99.pdf"/></article-meta></front><body><p><bold><italic>Background.</italic></bold>&#x02003;Isavuconazole (ISA) is a novel, water-soluble, broad-spectrum triazole antifungal available in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial (NCT00412893) assessed the efficacy and safety of ISA vs. voriconazole (VRC) in patients with invasive mold disease (IMD). Here we report on a pre-specified subset of patients from this trial who had proven/probable invasive aspergillosis (IA) (EORTC/MSG criteria) and received &#x02265;1 dose of the study drug.</p><p><bold><italic>Methods.</italic></bold>&#x02003;Patients were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, followed by 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. The primary efficacy endpoint was all-cause mortality (ACM) through Day 42. Overall success at end of treatment (EOT) and safety were also assessed. All diagnoses and outcomes were assessed by an independent, blinded, data-review committee. Safety data are presented as reported by the Investigator.</p><p><bold><italic>Results.</italic></bold>&#x02003;Overall 231 patients were included in this analysis (ISA n = 123; VRC n = 108). Patient characteristics, efficacy, and safety outcomes are shown in the table. Differences in drug-related AEs between ISA and VRC were statistically significant (p &#x0003c; 0.001).
</p><table-wrap id="OFU051TB23" orientation="portrait" position="float"><caption><p>Patient characteristics and outcomes</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1"><bold>ISA (n=123)</bold></th><th align="center" colspan="1" rowspan="1"><bold>VRC (n=108)</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic>Patient characteristics</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age (years), mean&#x000b1;SD</td><td colspan="1" rowspan="1">51&#x000b1;16</td><td colspan="1" rowspan="1">52&#x000b1;15</td></tr><tr><td colspan="1" rowspan="1">Male, n (%)</td><td colspan="1" rowspan="1">69 (56)</td><td colspan="1" rowspan="1">71 (66)</td></tr><tr><td colspan="1" rowspan="1">Primary underlying condition, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Acute myeloid leukemia</td><td colspan="1" rowspan="1">44 (36)</td><td colspan="1" rowspan="1">47 (44)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Acute lymphocytic leukemia</td><td colspan="1" rowspan="1">15 (12)</td><td colspan="1" rowspan="1">9 (8)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Non-Hodgkin's lymphoma</td><td colspan="1" rowspan="1">14 (11)</td><td colspan="1" rowspan="1">2 (2)</td></tr><tr><td colspan="1" rowspan="1">Other</td><td colspan="1" rowspan="1">49 (40)</td><td colspan="1" rowspan="1">49 (45)</td></tr><tr><td colspan="1" rowspan="1"><italic>Outcome&#x02013;Efficacy</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACM on Day 42, n (%)</td><td colspan="1" rowspan="1">23 (19)</td><td colspan="1" rowspan="1">24 (22)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Adjusted difference (ISA&#x02013;VRC), % (95% CI)</td><td align="center" colspan="2" rowspan="1">&#x02212;2.7 (&#x02212;12.9, 7.5)</td></tr><tr><td colspan="1" rowspan="1">ACM on Day 84</td><td colspan="1" rowspan="1">35 (29)</td><td colspan="1" rowspan="1">39 (36)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Adjusted difference (ISA&#x02013;VRC), % (95% CI)</td><td align="center" colspan="2" rowspan="1">&#x02212;5.7 (&#x02212;17.1, 5.6)</td></tr><tr><td colspan="1" rowspan="1">Overall success at EOT, n (%)</td><td colspan="1" rowspan="1">43 (35)</td><td colspan="1" rowspan="1">42 (39)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Adjusted difference (VRC&#x02013;ISA), % (95% CI)</td><td align="center" colspan="2" rowspan="1">4.0 (&#x02212;8.0, 15.9)</td></tr><tr><td colspan="1" rowspan="1"><italic>Outcome&#x02013;Safety, n (%)</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">AEs</td><td colspan="1" rowspan="1">118 (96)</td><td colspan="1" rowspan="1">106 (98)</td></tr><tr><td colspan="1" rowspan="1">Drug-related AEs</td><td colspan="1" rowspan="1">48 (39)</td><td colspan="1" rowspan="1">67 (62)</td></tr><tr><td colspan="1" rowspan="1">Serious AEs</td><td colspan="1" rowspan="1">71 (58)</td><td colspan="1" rowspan="1">71 (66)</td></tr><tr><td colspan="1" rowspan="1">Drug-related serious AEs</td><td colspan="1" rowspan="1">16 (13)</td><td colspan="1" rowspan="1">13 (12)</td></tr><tr><td colspan="1" rowspan="1">AEs leading to discontinuation</td><td colspan="1" rowspan="1">22 (18)</td><td colspan="1" rowspan="1">26 (24)</td></tr></tbody></table></table-wrap><p><bold><italic>Conclusion.</italic></bold>&#x02003;In patients with documented IA, ISA had comparable efficacy to VRC, but was better tolerated than the latter.</p><p><bold><italic>Disclosures.</italic></bold>&#x02003;<bold>D. Kontoyiannis</bold>, Merck, Inc.: Scientific Advisor and Speaker's Bureau, Consulting fee and Speaker honorarium; Astellas: Data review committee lead and Investigator, Compensaiton of data review committee involvement and Research grant; Pfizer: Investigator and Speaker's Bureau, Research grant and Speaker honorarium <bold>M. Lee</bold>, Astellas: Employee, Salary <bold>M. Nucci</bold>, Pfizer: Grant Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium Astellas: Scientific Advisor, Consulting fee <bold>I. Raad</bold>, Astellas: Grant Investigator, Grant recipient; Pfizer: Consultant, Consulting fee <bold>E. Bow</bold>, Astellas: Scientific Advisor, Consulting fee Pfizer: Investigator and Scientific Advisor, Consulting fee and Research grant <bold>V. A. Morrison</bold>, Astellas: Adjucation committee member, Consulting fee <bold>J. Baddley</bold>, Astellas: Consultant, Consulting fee; Merck: Consultant, Consulting fee; Pfizer: Consultant, Consulting fee <bold>B. Zeiher</bold>, Astellas: Employee, Salary <bold>R. Maher</bold>, Astellas: Employee, Salary <bold>W. Huang</bold>, Astellas: Employee, Salary <bold>K. A. Marr</bold>, Astellas: Consultant and Scientific Advisor, Consulting fee; Merck: Consultant, Consulting fee; Pfizer: Consultant, Consulting fee</p></body></article>